Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00899132 · ClinicalTrials.gov registry record
Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer
A clinical trial, sponsored by Case Comprehensive Cancer Center.
- Terminated
- Registry status
- 180
- Enrollment target
NCT00899132: Clinical Trial study, sponsored by Case Comprehensive Cancer Center.
NCT00899132 is a clinical trial that was terminated before completion, run by Case Comprehensive Cancer Center. The registered enrollment target is 180 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00899132 was terminated before completion, sponsored by Case Comprehensive Cancer Center.
- TERMINATED
- Registry status
- 180 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is evaluating a tumor marker for testicular cancer, skin cancer, small intestine cancer, and pancreatic cancer.
Interventions
- GENETIC protein expression analysis
- OTHER immunologic technique
- GENETIC in situ hybridization
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2007-02 |
| Est. Completion | 2012-09 |
Why NCT00899132 stopped before completion
NCT00899132 is an observational study that tracks outcomes without assigning an intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 3 interventions - of which protein expression analysis is the first listed.
NCT00899132 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00899132 about?
NCT00899132 is a clinical study titled "Studying a Tumor Marker for Testicular Cancer, Skin Cancer, Small Intestine Cancer, and Pancreatic Cancer". RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is evaluating a tumor marker for testicular cancer, skin cancer, small intestin...
What is the current status of trial NCT00899132?
This trial is currently terminated. The enrollment target is 180 participants. The study started on 2007-02. Estimated completion is 2012-09.
What interventions are being tested in trial NCT00899132?
The interventions under investigation include: protein expression analysis (GENETIC), immunologic technique (OTHER), in situ hybridization (GENETIC).
Who is sponsoring clinical trial NCT00899132?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia